Skip to search formSkip to main contentSkip to account menu

ALK Kinase Domain

Known as: ALK Tyrosine Kinase Receptor Kinase Domain, Anaplastic Lymphoma Kinase Tyrosine Kinase Domain, CD246 Tyrosine Kinase Domain 
The intracellular portion of the ALK tyrosine kinase receptor protein that confers tyrosine kinase enzymatic activity.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Abstract 3144: Prediction of ALK mutations associated with acquired resistance to lorlatinib
Anaplastic lymphoma kinase (ALK) rearrangements are important therapeutic targets in non-small cell lung cancer. They are… 
2017
2017
Abstract 1007: SHP2 inhibition restores sensitivity to ALK inhibition in resistant ALK-rearranged non-small cell lung cancer (NSCLC)
Despite development of highly potent and selective inhibitors (e.g., ceritinib, alectinib, lorlatinib) targeting anaplastic… 
2015
2015
Adopting ALK and LTK
Aberrant, uncontrolled activation of receptor tyrosine kinases (RTKs) is the “original sin” of many human cancers, in that this… 
2014
2014
Identification and Characterization of ALK Kinase Splicing Isoforms in Non–Small-Cell Lung Cancer
Introduction: Anaplastic lymphoma kinase (ALK) rearrangements are present in an important subset of non–small-cell lung cancer… 
2014
2014
Abstract 3719: Mechanisms of resistance to the second-generation alk inhibitor ap26113 in human npm-alk-positive anaplastic large cell lymphoma cells
ALK is a tyrosine kinase receptor involved in a broad range of solid and haematological tumors. It has been shown that about 70… 
2013
2013
Abstract 4456: Biochemical and structural characteristics of crizotinib-resistant ALK mutants.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Anaplastic lymphoma kinase (ALK), when aberrantly… 
2012
2012
Abstract 5594: ALK-driven lung cancer: Potential therapeutic strategies for treatment and prevention of drug resistance
The identification of oncogenic molecular drivers in non-small cell lung cancer (NSCLC) has allowed biologically targeted… 
2011
2011
Stratification of patients with neuroblastoma for targeted ALK inhibitor therapy.
9514 Background: Mutations in the ALK proto-oncogene are the major cause of hereditary neuroblastoma (NB), can be somatically… 
2011
2011
Characterization of novel potent and selective anaplastic lymphoma kinase (ALK) inhibitors.
e13600 Background: Aberrant forms of the anaplastic lymphoma kinase (ALK) have been implicated in the pathogenesis of multiple… 
2011
2011
Abstract 2327: Structural and kinetic characterization of crizotinib with wild-type and mutant anaplastic lymphoma kinase
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Dysregulation of Anaplastic Lymphoma Kinase (ALK… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)